Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 201–300 of 983

1. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
   Yiru Zhou, Yeye Kuang, Chan Wang, Yijian Yu, Lijuan Pan, Xiaotong Hu · 2024 · International Journal of Biological Sciences
2. Breathing new insights into the role of mutant p53 in lung cancer
   Tianwei Chen, Lauren M. Ashwood, Olga Kondrashova, Andreas Strasser, Gemma L. Kelly, Kate D. Sutherland · 2024 · Oncogene
3. Biomarkers for immunotherapy resistance in non-small cell lung cancer
   Catriona Rother, Tom John, Annie Ngai Man Wong · 2024 · Frontiers in Oncology
4. Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
   Pilar Garrido, Maria Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López‐Ríos, Juan Manuel Rosa-Rosa, José Palacios · 2017 · Therapeutic Advances in Medical Oncology
5. Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis
   Hongming Zhang, Liting Guo, Jibei Chen · 2020 · OncoTargets and Therapy
6. KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
   Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello · 2020 · European Journal of Cancer
7. Crosstalk of Exosomal Non-Coding RNAs in The Tumor Microenvironment: Novel Frontiers
   Zimo Jia, Jinlin Jia, Lihui Yao, Zhihan Li · 2022 · Frontiers in Immunology
8. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
   Haowei Wang, Fei Zhou, Meng Qiao, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Caicun Zhou · 2021 · Frontiers in Oncology
9. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
   Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Ståhl, Boris Kubuschok, H. Löffler, Ulrich Thorsten Hacker, G Hübner, Lena Weiss, Michael Bitzer et al. · 2023 · Nature Communications
10. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy
    Priyanka Uniyal, Vivek Kumar Kashyap, Tapan Behl, Deepak Parashar, Ravi Rawat · 2025 · Cancers
11. HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers
    Baotao Chen, Lin Li, Mengyuan Li, Xiaosheng Wang · 2020 · Cellular Oncology
12. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
    Anneloes L. Noordhof, Ronald A.M. Damhuis, Lizza E.L. Hendriks, Adrianus Johannes De Langen, Wim Timens, Ben J.W. Venmans, Wouter Heero van Geffen · 2021 · Lung Cancer
13. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma
    Aimin Jiang, Jingjing Wang, Na Liu, Xiaoqiang Zheng, Yimeng Li, Yuyan Ma, Haoran Zheng, Xue Chen, Chaoxin Fan, Rui Zhang et al. · 2022 · Frontiers in Genetics
14. Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies
    Elena Izquierdo, Daniela Vorholt, Stuart James Blakemore, Benedict Sackey, Janica L. Nolte, Verena Barbarino, Jan Schmitz, Nadine Nickel, Daniel Bachurski, Liudmila Lobastova et al. · 2022 · Blood
15. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
    Vitaly V. Chasov, Mikhail M. Zaripov, Regina Mirgayazova, Raniya Khadiullina, Ekaterina Zmievskaya, Irina Ganeeva, Aigul Kh. Valiullina, Albert Anatolyevich Rizvanov, Emil Bulatov · 2021 · Frontiers in Immunology
16. A Totipotent “All‐In‐One” Peptide Sequentially Blocks Immune Checkpoint and Reverses the Immunosuppressive Tumor Microenvironment
    Limin Zhang, Zhenqi Jiang, Xi Yang, Yixia Qian, Minxuan Wang, Shang Wu, Lingyun Li, Fei Jia, Zihua Wang, Zhiyuan Hu et al. · 2022 · Advanced Materials
17. Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
    Yosuke Miura, Noriaki Sunaga · 2018 · Cancers
18. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
    Peng Zhang, Yixuan Huang · 2021 · Journal of Hematology & Oncology
19. Down-regulation of A20 promotes immune escape of lung adenocarcinomas
    Kristina Breitenecker, Monika Homolya, Andreea Corina Luca, Veronika Lang, Christoph Trenk, Georg Petroczi, Julian Mohrherr, Jaqueline Horvath, Stefan Moritsch, Lisa Haas et al. · 2021 · Science Translational Medicine
20. Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
    Fan Zhang, Jinliang Wang, Yu Xu, Shangli Cai, Tao Li, Guoqiang Wang, Chengcheng Li, Lei Zhao, Yi Hu · 2022 · npj Precision Oncology
21. Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
    Xiaoyan Wang, Bingchen Wu, Zhengqing Yan, Guoqiang Wang, Shiqing Chen, Jian Zeng, Feng Tao, Bichun Xu, Honggang Ke, Mei Li · 2021 · Frontiers in Oncology
22. Hyperprogression: A novel response pattern under immunotherapy
    Xuejiao Han, Aqu Alu, Yinan Xiao, Yu‐quan Wei, Xia‐wei Wei · 2020 · Clinical and Translational Medicine
23. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
    Qiong Lyu, Anqi Lin, Manming Cao, Xun Xu, Peng Luo, Jian Zhang · 2020 · Cancer Control
24. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas
    Song Han, Peng-Fei Wang, Hong-Qing Cai, Jing-Hai Wan, Shou-Wei Li, Ze-Huan Lin, Chun-Jiang Yu, Chang-Xiang Yan · 2021 · Aging
25. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies
    Yizhen Fu, Zhenyun Yang, Zili Hu, Zhoutian Yang, Yangxun Pan, Jinbin Chen, Juncheng Wang, Dandan Hu, Zhongguo Zhou, Li Xu et al. · 2022 · Hepatology International
26. Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
    Chin Sern Yiong, Tzu Ping Lin, Vivian Lim, Tan Boon Toh, Valerie Shiwen Yang · 2023 · Biomarker Research
27. The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
    Shuhang Wang, Miaomiao Jiang, Zuozhen Yang, Xiaoyun Huang, Ning Li · 2020 · Genes & Diseases
28. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
    Fei Zhou, Yan Huang, Weijing Cai, Jin Li, Chunxia Su, Shengxiang Ren, Chunyan Wu, Caicun Zhou · 2021 · Lung Cancer
29. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen, Gao, Yanli, Chang, Pengyu · 2021 · Cancers
30. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
    Natalie I. Vokes, Kelsey Pan, Xiuning Le · 2023 · Therapeutic Advances in Medical Oncology
31. scAB detects multiresolution cell states with clinical significance by integrating single-cell genomics and bulk sequencing data
    Qinran Zhang, Suoqin Jin, Xiufen Zou · 2022 · Nucleic Acids Research
32. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer
    Peng Song, Lei Guo, Wenbin Li, Fan Zhang, Jianming Ying, Shugeng Gao · 2018 · Journal of Immunotherapy
33. Functional Diversity of p53 in Human and Wild Animals
    Yi Li, Mengchen Zhang, Xiaokang Xu, Yang Zhao, Mahanand Chatoo, Tao Zhu, Hong Deng, Eviatar Nevo, Ji-Zeng Du, Xuequn Chen · 2019 · Frontiers in Endocrinology
34. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
    Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino et al. · 2019 · Therapeutic Advances in Medical Oncology
35. Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer
    Teresa Ho, Rasha Msallam · 2021 · Cells
36. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
    Hang Sheng Yang, Xinyi Zhou, Dongliang Fu, Chenqin Le, Jiafeng Wang, Quan Zhou, Xiangrui Liu, Ying Yuan, Kefeng Ding, Qian Xiao · 2022 · 癌症：英文版
37. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer
    Siteng Chen, Ning Zhang, Jialiang Shao, Tao Wang, Xiang Wang · 2019 · Journal of Cancer
38. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
    Yongting Liu, Bin Xie, Qiong Chen · 2023 · Journal of Translational Medicine
39. Bioinformatics analysis of DNMT1 expression and its role in head and neck squamous cell carcinoma prognosis
    Jili Cui, Zheng Lian, Yuanyuan Zhang, Miaomiao Xue · 2021 · Scientific Reports
40. A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
    Xi Jiao, Xin Lan Wei, Shuang Li, Chang Xin Liu, Huan Chen, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng et al. · 2021 · npj Precision Oncology
41. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
    Jun Ho Ji, Sang Yun Ha, Danbi Lee, K. Nathan Sankar, Ekaterina K. Koltsova, Ghassan K. Abou‐Alfa, Ju Dong Yang · 2023 · International Journal of Molecular Sciences
42. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma
    Jie Peng, Dan Zou, Xudong Zhang, Honglian Ma, Li-Jie Han, Biao Yao · 2024 · Journal of Translational Medicine
43. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer
    Xiangfeng Shen, Yuan Zhao, Guolong Liu, Hong-Lan Zhou, Jingjing Fan, Lihong Zhang, Yulin Li, Yishu Wang, Jiyong Liang, Zhixiang Xu · 2020 · Life Sciences
44. Biomarkers related to immune checkpoint inhibitors therapy
    Na Li, Xin Hou, Shaogang Huang, Risheng Tai, Lei Lei, Siyu Li, Adina Abuliz, Geng Wang, Shanru Yang · 2022 · Biomedicine & Pharmacotherapy
45. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel
    Wu Zhuang, Junxun Ma, Xudong Chen, Guoqiang Wang, Jing Nan Lu, Yanan Chen, Hua Dong, Shangli Cai, Yuzi Zhang, Xiaochen Zhao et al. · 2018 · Journal of Cancer
46. Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer
    Yan Zhao, Yueping Liu, Yunlong Jia, Xiaoxiao Wang, Jiankun He, Shuman Zhen, Jiali Wang, Lihua Liu · 2022 · Journal of Cancer Research and Clinical Oncology
47. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
    Kim Alan Brogden, Deepak Parashar, Andrea R. Hallier, Terry A. Braun, Qian Fang, Naiyer A. Rizvi, Aaron Bossler, Mohammed M. Milhem, Timothy An-thy Chan, Taher Abbasi et al. · 2018 · BMC Cancer
48. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
    Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Désirèe Deandreis · 2021 · Cancers
49. The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
    Hanxiao Chen, Dingzhi Huang, Gen Lin, Xue Yang, Minglei Zhuo, Yujia Chi, Xiaoyu Zhai, Bo Jia, Jingjing Wang, Yuyan Wang et al. · 2022 · Cancer Medicine
50. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB
    Jia Chen, Sheng Wei, Tianye Zhao, Xunlei Zhang, Yilang Wang, Xiaodong Zhang · 2022 · Disease Markers
51. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li, Lei Yang, Yuanyuan Wang, Lingchan Wang, Gang Chen, Li Zhang, Dongchang Wang · 2023 · BMC Bioinformatics
52. Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
    Chengde Wu, Xiang Rao, Wei Li Lin · 2020 · Cancer Medicine
53. Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
    Xiang‐mei Wen, Zi‐jun Xu, Ye Jin, Pei‐hui Xia, Ji‐chun Ma, Wei Qian, Jiang Lin, Jun Qian · 2021 · Frontiers in Immunology
54. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research
    Galaxia M. Rodriguez, Kristianne J.C. Galpin, David P. Cook, Edward Yakubovich, Vincent Maranda, Elizabeth A. Macdonald, Juliette Wilson‐Sanchez, Anjali L. Thomas, Joanna E. Burdette, Barbara C. Vanderhyden · 2022 · Cancer Research Communications
55. A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma
    Chuanbing Zhao, Zhengle Zhang, Jing Tao · 2022 · Frontiers in Oncology
56. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
    Jie Peng, Dan Zou, 龚五星, Shuai Kang, Lijie Han · 2020 · OncoImmunology
57. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
    Yanjun Xu, Hui Li, Zhiyu Huang, Kaiyan Chen, Xiaoqing Yu, Jiamin Sheng, Hanhan Zhang, Yun Fan · 2020 · Translational Lung Cancer Research
58. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Congyu Shi, Shan Liu, Xudong Tian, Xiaoyi Wang, Pan Gao · 2021 · BMC Cancer
59. Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
    Wenjing Zhang, Yunfeng Tang, Yuxian Guo, Yujia Kong, Fuyan Shi, Chao Sheng, Suzhen Wang, Qinghua Wang · 2022 · npj Precision Oncology
60. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
    Zhimin Zeng, Xiaoying Qian, Fanrong Liu, Yong Wang, Yong Yuan, Fang Chen, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu et al. · 2022 · Frontiers in Immunology
61. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
    Kaili Zhu, Fei Su, Jingru Yang, Ruowen Xiao, Rui-yue Wu, Meng-yue Cao, Xiaoling Ling, Tao Zhang · 2024 · Molecular Biology Reports
62. The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
    Chongya Zhai, Xiaoling Zhang, Lulu Ren, Liangkun You, Qin Pan, Hongming Pan, Weidong Han · 2021 · Frontiers in Oncology
63. Targeting KRAS in Non-Small Cell Lung Cancer
    E. Corral de la Fuente, Maria Eugenia Olmedo, Ana Gómez Rueda, Yolanda Lage, Pilar Garrido · 2022 · Frontiers in Oncology
64. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
    Mo Shen, Rongbin Qi, Justin Ren, Dongqing Lv, Haihua Yang · 2022 · Frontiers in Oncology
65. Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
    Tao Wang, Tianye Li, Baiqing Li, Jiahui Zhao, Zhi Li, Mingyi Sun, Yan Li, Yanjiao Zhao, Shidi Zhao, Weiguang He et al. · 2022 · Frontiers in Immunology
66. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study
    Betzabel N. Cajiao Garcia, Léon C.L.T. van Kempen, Chantal C. H. J. Kuijpers, Ed M. D. Schuuring, Stefan M. Willems, Anthonie J. van der Wekken · 2022 · Lung Cancer
67. An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
    Hongquan Chen, Renxi Lin, Weibin Lin, Qing Chen, Dongjie Ye, Jing Li, Jinan Feng, Wenxiu Cheng, Mingfang Zhang, Yuanlin Qi · 2022 · Scientific Reports
68. TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
    Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li et al. · 2021 · Therapeutic Advances in Medical Oncology
69. Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer
    Fen Wang, Mingyi Yang, Wei‐Chi Luo, Qing Zhou · 2022 · Journal of the National Cancer Center
70. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
    Masayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Junko Tanizaki, Takayuki Takahama, Koji Haratani, Kazuto Nishio, Kazuhiko Nakagawa · 2018 · Oncotarget
71. Strategies for Predicting Response to Checkpoint Inhibitors
    Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub · 2018 · Current Hematologic Malignancy Reports
72. AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers
    Axel Gschwind, Stephan Ossowski · 2025 · Cancers
73. Targeting PD-L1 Protein: Translation, Modification and Transport
    Ran Wei, Libin Guo, Qingshui Wang, Jin Miao, Hang Fai Kwok, Yao Lin · 2018 · Current Protein and Peptide Science
74. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
    Mahsa Saliani, Razieh Jalal, Mohammad Reza Ahmadian · 2019 · Cancer Biology and Medicine
75. PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
    Ao-Ran Dong, Yiming Zhao, Zhi-Hua Li, Hai Hu · 2020 · Journal of Gene Medicine
76. Shifting the paradigms for tumor suppression: lessons from the p53 field
    Thibaut Barnoud, Alexandra Indeglia, Maureen E. Murphy · 2021 · Oncogene
77. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
    Sunetra Das, Rupa Idate, Daniel P. Regan, Jared Scott Fowles, Susan E. Lana, Douglas H. Thamm, Daniel L. Gustafson, Dawn L. Duval · 2021 · Communications Biology
78. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
    Marco Cefalì, Samantha Epistolio, Giulia Ramelli, Dylan Mangan, Francesca Molinari, Vittoria Martin, Stefania Freguia, Luca Mazzucchelli, Patrizia Froesch, Milo Frattini et al. · 2022 · Journal of Clinical Medicine
79. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers
    Ruyin Chen, Dandan Zheng, Qiong Li, Shuaishuai Xu, Chanqi Ye, Qi Jiang, Feifei Yan, Yunlu Jia, Xiaochen Zhang, Jian Ruan · 2022 · Cancer Letters
80. Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer
    Khoosheh Khayati, Vrushank Dharmesh Bhatt, Taijin Lan, Fawzi Alogaili, Wenping Wang, Enrique Lopez, Zhixian Sherrie Hu, Samantha Gokhale, Liam D. Cassidy, Masashi Narita et al. · 2022 · Cancer Research
81. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
    Jingyuan Wang, Joanne Xiu, Yasmine Baca, Hiroyuki Arai, Francesca Battaglin, Natsuko K. Kawanishi, Shivani Soni, Wenjing Zhang, Joshua Millstein, Anthony Frank Shields et al. · 2021 · Annals of Oncology
82. TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma
    Anyuan Zhong, Ting Chen, Tong Zhou, Zengli Zhang, Minhua Shi · 2021 · Frontiers in Pharmacology
83. An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
    Wenjing Zhang, Yuting Li, Juncheng Lyu, Fuyan Shi, Yujia Kong, Chao Sheng, Suzhen Wang, Qinghua Wang · 2021 · Cancer Science
84. Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
    Mingyu Zhu, Lu Zhang, Haiyan Cui, Qiang Zhao, Hao Wang, Baochao Zhai, Richeng Jiang, Zhansheng Jiang · 2022 · Frontiers in Immunology
85. Precision targeted therapy for EGFR mutation‐positive NSCLC : Dilemmas and coping strategies
    Ying Meng, Rilan Bai, Jiuwei Cui · 2023 · Thoracic Cancer
86. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non–small-cell lung carcinoma
    Ruihan Luo, Jing Song, Xiao Xiao, Zhengbo Xie, Zhihao Zhao, Wanfeng Zhang, Shiqi Miao, Yongyao Tang, Longke Ran · 2020 · Aging
87. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
    Nerea Otegui, Maeva Houry, Imanol Arozarena, Diego Serrano, Esther Redín, Francisco Expósito, Sergio León, Karmele Valencia, Luis M. Montuenga, Alfonso Calvo · 2023 · Cancers
88. Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
    Mingming Jia, Linli Yao, Qin Yang, Tian H. Chi · 2020 · Frontiers in Oncology
89. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
    Yiting Sun, Jianchun Duan, Wenfeng Fang, Zhijie Wang, Xinyang Du, Xin Wang, Chengcheng Li, Shangli Cai, Jie Zhao, Sini Li et al. · 2021 · BMC Medicine
90. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
    Elona Cekani, Samantha Epistolio, Giulia Dazio, Marco Cefalì, Luciano Wannesson, Milo Frattini, Patrizia Froesch · 2022 · Cancers
91. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma
    Hong Peng, Yi Zhang, Zhiwei Zhou, Yu Guo, Xiaohui Huang, Kenneth D. Westover, Zhaohui Zhang, Bin Chen, Yunpeng Hua, Shaoqiang Li et al. · 2019 · EBioMedicine
92. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
    Miriam Blasi, Jonas Kuon, H Lüders, Daniel Misch, Diego Erich Kauffmann-Guerrero, Moritz Hilbrandt, Daniel N. Kazdal, Roger-Fei Falkenstern-Ge, Björn W. Hackanson, Sebastian Dintner et al. · 2024 · European Journal of Cancer
93. Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
    Wei Ye, Xin Lu, Yue Qiao, Wen‐Bin Ou · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
94. Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI ‐driven stemness‐related gene signature
    Bicheng Ye, Ge Hongting, Wen Zhuang, Cheng Chen, Shulin Yi, Xinyan Tang, Aimin Jiang, Yating Zhong · 2024 · Journal of Cellular and Molecular Medicine
95. Comprehensive genomic profile of cholangiocarcinomas in China
    Weijun Tian, Weiyu Hu, Xiaoling Shi, Peng Liu, Xiang Ma, Wei Zhao, Linlin Qu, Shuirong Zhang, Weiwei Shi, Angen Liu et al. · 2020 · Oncology Letters
96. FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.
    Mi-Heon Lee, Jane Yanagawa, Linh My Tran, Tonya C. Walser, Bharti Bisht, Eileen Fung, Stacy J. Park, Gang Zeng, Kostyantyn Krysan, William D. Wallace et al. · 2020 · PubMed Central
97. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
    Qinghua Wang, Yichen Yang, Meng Yang, Xiangchun Li, Kexin Chen · 2020 · Aging
98. Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
    Joshua C. Rosen, Jessica Weiss, Nhu‐An Pham, Quan Li, Sebastião N. Martins-Filho, Yuhui Wang, Ming‐Sound Tsao, Nadeem Moghal · 2021 · Translational Oncology
99. Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
    Jiyun Lee, Aaron C. Tan, Siqin Zhou, Shinkyo Yoon, Si‐Yang Maggie Liu, Ken Masuda, Hidetoshi Hayashi, Ullas Batra, Dong‐Wan Kim, Yasushi Goto et al. · 2021 · JTO Clinical and Research Reports
100. Impact of cancer cell-intrinsic features on neutrophil behavior
     Danique E. M. Duits, Karin E. de Visser · 2021 · Seminars in Immunology